{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:34:31Z","timestamp":1794980071618,"version":"4.9.1"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>\n                    <jats:italic toggle=\"yes\">Mycoplasma pneumoniae<\/jats:italic>\n                    pneumonia incidence was much decreased worldwide from 2020 to 2023 due to global infection control measures against the novel coronavirus epidemic. However, it resurfaced in the second half of 2023 following the relaxation of infection control measures, and the threat of macrolide-resistant\n                    <jats:italic toggle=\"yes\">M. pneumoniae<\/jats:italic>\n                    has reemerged, especially in East Asian countries. A reduction of the rate of macrolide-resistant\n                    <jats:italic toggle=\"yes\">M. pneumoniae<\/jats:italic>\n                    was seen in Japan and a part of Taiwan during the pandemic, so it is important to minimize selection pressure favoring macrolide-resistant\n                    <jats:italic toggle=\"yes\">M. pneumoniae<\/jats:italic>\n                    by avoiding overuse of macrolides.\n                  <\/jats:p>","DOI":"10.1097\/inf.0000000000005019","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:19:17Z","timestamp":1760541557000},"page":"e446-e449","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Recent Global Trends of Macrolide-resistant Mycoplasma pneumoniae: Why Has the Macrolide-resistant Rate Decreased in Japan?"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6277-3725","authenticated-orcid":false,"given":"Kazunobu","family":"Ouchi","sequence":"first","affiliation":[{"name":"Kawasaki University of Medical Welfare"},{"name":"Department of Medical Welfare for Children, Kawasaki Medical School, Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Oishi","sequence":"additional","affiliation":[{"name":"Department of Medical Welfare for Children, Kawasaki Medical School, Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"R1-20260615","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1128\/CMR.00114-16","article-title":"Mycoplasma pneumoniae from the respiratory tract and beyond.","volume":"30","author":"Waites","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"R3-20260615","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0022-3476(70)80485-1","article-title":"Resistance of Mycoplasma pneumoniae to erythromycin and other antibiotics.","volume":"76","author":"Niitsu","year":"1970","journal-title":"J Pediatr"},{"key":"R4-20260615","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1348-0421.2001.tb01293.x","article-title":"Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro.","volume":"45","author":"Okazaki","year":"2001","journal-title":"Microbiol Immunol"},{"key":"R5-20260615","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s10156-009-0021-4","article-title":"Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia.","volume":"16","author":"Morozumi","year":"2010","journal-title":"J Infect Chemother"},{"key":"R6-20260615","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3201\/eid2310.170106","article-title":"Macrolide-resistant Mycoplasma pneumoniae infection, Japan, 2008-2015.","volume":"23","author":"Tanaka","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"R7-20260615","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1128\/AAC.01806-13","article-title":"More complications occur in macrolide-resistant than in macrolide-sensitive Mycoplasma pneumoniae pneumonia.","volume":"58","author":"Zhou","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R8-20260615","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.3390\/microorganisms12091806","article-title":"Clinical manifestations, macrolide resistance, and treatment utilization trends of Mycoplasma pneumoniae pneumonia in children and adolescents in South Korea.","volume":"12","author":"Lee","year":"2024","journal-title":"Microorganisms"},{"key":"R9-20260615","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s12519-024-00831-0","article-title":"Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.","volume":"20","author":"Wang","year":"2025","journal-title":"World J Pediatr"},{"key":"R10-20260615","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3390\/jcm8050726","article-title":"Early corticosteroid therapy for Mycoplasma pneumoniae pneumonia irrespective of used antibiotics in children.","volume":"8","author":"Yang","year":"2019","journal-title":"J Clin Med"},{"key":"R11-20260615","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/tropej\/fmu022","article-title":"Early treatment with corticosteroids in patients with Mycoplasma pneumoniae pneumonia: a randomized clinical trial.","volume":"60","author":"Huang","year":"2014","journal-title":"J Trop Pediatr"},{"key":"R12-20260615","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.resinv.2021.09.009","article-title":"Atypical pneumonia: pathophysiology, diagnosis, and treatment.","volume":"60","author":"Miyashita","year":"2022","journal-title":"Respir Investig"},{"key":"R13-20260615","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00284-022-03103-0","article-title":"Insight into the pathogenic mechanism of Mycoplasma pneumoniae.","volume":"80","author":"Hu","year":"2022","journal-title":"Curr Microbiol"},{"key":"R14-20260615","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1086\/591915","article-title":"The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection.","volume":"198","author":"Tagliabue","year":"2008","journal-title":"J Infect Dis"},{"key":"R15-20260615","doi-asserted-by":"crossref","first-page":"piae117","DOI":"10.1093\/jpids\/piae117","article-title":"Macrolide-resistant Mycoplasma pneumoniae, North Dakota 2024.","volume":"14","author":"Douvoyiannis","year":"2025","journal-title":"J Pediatr Infect Dis Soc"},{"key":"R16-20260615","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fmicb.2016.00974","article-title":"Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment.","volume":"7","author":"Pereyre","year":"2016","journal-title":"Front Microbiol"},{"key":"R17-20260615","doi-asserted-by":"crossref","first-page":"101019","DOI":"10.1016\/j.lanmic.2024.101019","article-title":"Global spatiotemporal dynamics of Mycoplasma pneumoniae re-emergence after COVID-19 pandemic restrictions: an epidemiological and transmission modelling study.","volume":"6","year":"2025","journal-title":"Lancet microbe"},{"key":"R18-20260615","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.3201\/eid3008.231596","article-title":"Macrolide-resistant Mycoplasma pneumoniae infections among children before and during COVID-19 pandemic, Taiwan, 2017\u20132023.","volume":"30","author":"Wu","year":"2024","journal-title":"Emerging Infect Dis"},{"key":"R19-20260615","doi-asserted-by":"crossref","first-page":"1427702","DOI":"10.3389\/fmicb.2024.1427702","article-title":"An outbreak of Mycoplasma pneumoniae in children after the COVID-19 pandemic, Shanghai, China, 2023.","volume":"15","author":"Zhu","year":"2024","journal-title":"Front Microbiol"},{"key":"R20-20260615","first-page":"262","article-title":"Post-COVID-19 pandemic rebound of macrolide-resistant Mycoplasma pneumoniae infection: a descriptive study.","volume":"13","author":"Xing","year":"2024","journal-title":"Antibiotics (Basel, Switzerland)"},{"key":"R21-20260615","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12985-024-02458-z","article-title":"Mycoplasma pneumoniae infection outbreak in Guangzhou, China after COVID-19 pandemic.","volume":"21","author":"Li","year":"2024","journal-title":"Virol J"},{"key":"R22-20260615","doi-asserted-by":"crossref","first-page":"1424554","DOI":"10.3389\/fcimb.2024.1424554","article-title":"Epidemiological characteristics of mycoplasma pneumoniae in hospitalized children before, during, and after COVID-19 pandemic restrictions in Chongqing, China.","volume":"14","author":"You","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"R23-20260615","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3201\/eid3005.231632","article-title":"Novel variant and known mutation in 23S rRNA gene of Mycoplasma pneumoniae, Northern Vietnam, 2023.","volume":"30","author":"Nguyen","year":"2024","journal-title":"Emerg Infect Dis"},{"key":"R24-20260615","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1007\/s15010-024-02336-4","article-title":"The high-incidence period of Mycoplasma pneumoniae infections 2023\/2024 in southeast Germany was associated with a low level of macrolide resistance.","volume":"52","author":"Dumke","year":"2024","journal-title":"Infection"},{"key":"R25-20260615","doi-asserted-by":"crossref","first-page":"e893","DOI":"10.1016\/S2542-5196(21)00280-1","article-title":"Global antibiotic consumption and usage in humans, 2000-18: a spatial modelling study.","volume":"5","author":"Browne","year":"2021","journal-title":"Lancet Planet Health"},{"key":"R26-20260615","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jiac.2020.10.007","article-title":"Recent acute reduction in macrolide-resistant Mycoplasma pneumoniae infections among Japanese children.","volume":"27","author":"Nakamura","year":"2021","journal-title":"J Infect Chemother"},{"key":"R27-20260615","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.3201\/eid2609.191575","article-title":"Sequence type changes associated with decreasing macrolide-resistant Mycoplasma pneumoniae, Japan.","volume":"26","author":"Morozumi","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"R28-20260615","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.3390\/jcm11071782","article-title":"Recent trends in the epidemiology, diagnosis, and treatment of macrolide-resistant Mycoplasma pneumoniae.","volume":"11","author":"Oishi","year":"2022","journal-title":"J Clin Med"},{"key":"R29-20260615","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2131\/jts.27.219","article-title":"Comparative articular toxicology of garenoxacin, a novel quinolone antimicrobial agent, in juvenile beagle dogs.","volume":"27","author":"Nagai","year":"2002","journal-title":"J Toxicol Sci"},{"key":"R30-20260615","first-page":"12","article-title":"Toxicity studies of tosufloxacin tosilate hydrate in juvenile animals and class effects studies.","volume":"58","author":"Furubo","year":"2010","journal-title":"Jpn J Chemother"},{"key":"R33-20260615","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1097\/INF.0000000000004041","article-title":"Guidelines for the management of respiratory infectious diseases in children in Japan 2022.","volume":"42","author":"Ishiwada","year":"2023","journal-title":"Peditr Infect Dis J"},{"key":"R35-20260615","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1128\/AAC.00663-13","article-title":"Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients.","volume":"57","author":"Kawai","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R36-20260615","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s10156-009-0715-7","article-title":"A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients.","volume":"15","author":"Matsubara","year":"2009","journal-title":"J Infect Chemother"},{"key":"R37-20260615","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/cid\/cis784","article-title":"Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae in a 2011 outbreak among Japanese children.","volume":"55","author":"Okada","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R38-20260615","doi-asserted-by":"crossref","first-page":"e0173635","DOI":"10.1371\/journal.pone.0173635","article-title":"Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosfloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients.","volume":"12","author":"Ishiguro","year":"2017","journal-title":"PLoS One"},{"key":"R39-20260615","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.3390\/microorganisms10122428","article-title":"Recent trends in antimicrobial susceptibility among Mycoplasma pneumoniae isolated from Japanese children.","volume":"10","author":"Oishi","year":"2022","journal-title":"Microorganisms"},{"key":"R40-20260615","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jmii.2020.10.002","article-title":"Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children.","volume":"54","author":"Tsai","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"key":"R41-20260615","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/14787210.2018.1414599","article-title":"Antimicrobial therapy of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.","volume":"16","author":"Lee","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R43-20260615","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1099\/jmm.0.47634-0","article-title":"Genotyping analysis of Mycoplasma pneumoniae clinical strains in Japan between 1995 and 2005: type shift phenomenon of M. pneumoniae clinical strains.","volume":"57","author":"Kenri","year":"2008","journal-title":"J Med Microbiol"},{"key":"R44-20260615","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3389\/fcimb.2020.00385","article-title":"Periodic genotype shifts in clinically prevalent Mycoplasma pneumoniae strains in Japan.","volume":"10","author":"Kenri","year":"2020","journal-title":"Front Cell Infect Microbiol"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000005019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T18:00:11Z","timestamp":1781546411000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000005019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005019","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]}}}